Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TO-208 Phase III Study in Molluscum Contagiosum
jRCT2041220039Phase 3Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in molluscum contagiosum (MC) comparing TO-208 dermal application with Placebo dermal application (2 arms). Primary endpoint: Proportion of subjects achieving complete clearance of all treatable molluscum lesions at Visit 7 or discontinuation. Started Jul 2022; status: completed.
02
Drugs
cantharidin
03
Conditions
molluscum contagiosum (MC)
Beyond the preview
Go deeper on jRCT2041220039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220039.